6-methyl-2,4-dioxo-heptanoic acid | 247180-26-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: 6-methyl-2,4-dioxo-heptanoic acid
• 英文别名: 6-Methyl-2,4-dioxo-heptansaeure；6-Methyl-2,4-dioxoheptanoic acid
• CAS: 247180-26-3
• 化学式: C₈H₁₂O₄
• 分子量: 172.181
• InChiKey: ZCSPDZIMLGBCJX-UHFFFAOYSA-N

物化性质

• 熔点：
  48-49 °C
• 沸点：
  271.1±23.0 °C(Predicted)
• 密度：
  1.149±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  71.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-methyl-2,4-dioxo-heptanoic acid 、 alkaline earth salt of/the/ methylsulfuric acid 生成 异戊酸 、 丙酮酸
  参考文献：
  名称：

  Meister; Greenstein, Journal of Biological Chemistry, 1948, vol. 175, p. 575

  摘要：

  DOI：
• 作为产物：
  描述：

  乙基6-甲基-2,4-二氧亚基庚酯 在 sodium hydroxide 作用下， 生成 6-methyl-2,4-dioxo-heptanoic acid
  参考文献：
  名称：

  Meister; Greenstein, Journal of Biological Chemistry, 1948, vol. 175, p. 575

  摘要：

  DOI：

文献信息

• Urethane catalyst based on zirconium acetylacetonate
  申请人：King Industries, Inc.

  公开号：EP1163956A1

  公开（公告）日：2001-12-19

  The present invention is directed to novel metal organocomplexes as catalysts for the reaction of compounds with isocyanate and hydroxy functional groups to form urethane and/or polyurethane and the process employing such catalysts. More particularly, the present invention is directed to catalysts comprising a mixture of tetrakis-(2,4-pentanedionato) zirconium and a compound selected from the group consisting of a diketone:         R1COCH2COR2     (II) and         R1OCOCH2COR2     (III) wherein each of R1 and R2 is a branched or linear C1-C20 hydrocarbon and the total number of carbons in R1+R2 is at least 4. These novel catalysts are useful for the production of urethanes and polyurethanes which are important in many industrial applications, such as: coatings, foams, adhesives, sealants, and reaction injection molding (RIM) plastics.

  本发明涉及作为催化剂的新型金属有机络合物，用于使具有异氰酸酯和羟基官能团的化合物反应生成聚氨酯和/或聚氨酯，以及采用这种催化剂的工艺。更具体地说，本发明涉及由四-(2,4-戊二酮酸)锆和选自由二酮组成的组的化合物的混合物组成的催化剂： R1COCH2COR2 (II) 和 r1ococh2cor2 (iii) 这些新型催化剂可用于生产聚氨酯和聚氨酯，它们在许多工业应用中都非常重要，例如：涂料、泡沫、粘合剂、密封剂和反应注塑成型（RIM）塑料。
• Metal complexes containing cyclopentadienyl ligands
  申请人：MERCK PATENT GMBH

  公开号：US11312730B2

  公开（公告）日：2022-04-26

  Metal complexes including cyclopentadienyl ligands and methods of using such metal complexes to prepare metal-containing films are provided.

  本发明提供了包括环戊二烯配体的金属络合物以及使用此类金属络合物制备含金属薄膜的方法。
• [EN] METAL COMPLEXES CONTAINING CYCLOPENTADIENYL LIGANDS<br/>[FR] COMPLEXES MÉTALLIQUES CONTENANT DES LIGANDS DE CYCLOPENTADIÉNYLE
  申请人：MERCK PATENT GMBH

  公开号：WO2018086730A9

  公开（公告）日：2019-07-11
• Lack of Pharmacokinetic Interaction between Sumatriptan and Naproxen
  作者：P. Srinivasu、D. Rambhau、B. Ramesh Rao、Y. Madhusudan Rao

  DOI：10.1177/00912700022008621

  日期：2000.1.1

  Sumatriptan is a 5HT(1D) agonist used in the treatment of migraine. Nonsteroidal anti-inflammatory drugs, beta-blockers, and calcium channel-blocking antagonists are used in the prophylaxis of migraine. Hence, there is a need to investigate the interaction of these prophylactic drugs with sumatriptan. The interaction of sumatriptan with propranolol, flunarizine, pizotifen, and butorphanol were reported earlier. Naproxen is shown to be effective in prophylactic treatment of migraine. In this study, the authors have investigated the circadian rhythm effect of naproxen on the pharmacokinetics of sumatriptan at 1000 and 2200 hours. Twelve healthy volunteers were treated with 100 mg sumatriptan succinate either alone or along with 500 mg naproxen orally at either 1000 or 2200 hours in a randomized Latin square design with a washout period of 10 days. Serum samples were collected at predetermined time intervals and analyzed for unchanged sumatriptan by highperformance liquid chromatography. The pharmacokinetic parameters were calculated by using model-independent methods. Naproxen had no statistically significant (p > 0.05) effect on any pharmacokinetic parameters of sumatriptan both at 1000 and 2200 hours treatment. The results of this study suggest that no alteration in the sumatriptan dosage will be necessary for migraine patients taking naproxen prophylactic therapy. (C) 2000 the American College of Clinical Pharmacology.
• NOVEL ZIRCONIUM URETHANE CATALYSTS
  申请人：KING INDUSTRIES, INC.

  公开号：EP1021245A1

  公开（公告）日：2000-07-26